Shares of ChemoCentryx (CCXI - Get Report) were up 23% to $8.27 in premarket trading on Friday. The Mountain View, Calif.-based ChemoCentryx is scheduled to release its fourth-quarter results after the market close on March 14. The company is developing medications that target inflammatory and autoimmune diseases, and cancer.
Shares of Carlsbad, Calif.-based Ionis Pharmaceuticals (IONS - Get Report) were down 6.6% to $42.80 after Goldman Sachs downgraded the stock to sell from neutral and reduced its price target to $25 from $28. "IONS is an early pioneer of antisense RNA therapies and while the technology has the potential to address "undruggable" targets in broad therapeutic areas, a lackluster track record of developing successful drugs along with platform toxicity indicates a "show me" story," wrote Goldman analysts in a note on Friday.
Other premarket movers include Zogenix (ZGNX - Get Report) , whose shares were down 6.3% to $8.95. The Emeryville, Calif.-based company, which develops therapies for orphan and central nervous system disorders, after the market close on Thursday reported a fourth-quarter net loss of $23.5 million, or $0.95 per share, compared with a net loss of $8.8 million, or $0.36 per share, in the year-ago period. Revenue was $11 million, compared with $6.1 million in the same period last year.